Nuclear Medicine

Prostate Cancer

Questions discussed in this category

In light of the pending overall survival data and reported declines in quality of life associated with the PSMAddition trial, how do you envision incorporating Pluvicto into the management of mHSPC?

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

1 Answer available

Are there any contraindications to Pluvicto therapy you personally use, given that there are none directly provided by the manufacturer?

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

3 Answers available

How do you sequence Pluvicto vs docetaxel in a fit, chemotherapy-naïve patient with high-volume PSMA-avid mCRPC progressing on an ARPI?

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

2 Answers available

What criteria are you using for retreatment with Pluvicto (Lu-177) in those who maintain a good performance status and appropriate lab work?

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

3 Answers available

Does the possibility of future Lu-177–PSMA therapy change your current threshold to offer earlier metastasis-directed RT in oligometastatic prostate cancer?

Would the extent of marrow exposure at the treatment site affect your decision-making? This question is part of our collaboration with ASTRO to highl...

2 Answers available

Can you give Pluvicto with concurrent palliative EBRT?

If so, do you modify your external beam dose? This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidi...

2 Answers available

When selecting mCRPC patients for Pluvicto, which baseline variables do you find most useful or predictive of potential hematologic toxicity?

e.g., baseline counts, prior taxane exposure, prior EBRT, imaging evidence of marrow-involving disease. This question is part of our collaboration wi...

1 Answer available

Do you modify dosing and monitoring of Lu-177–PSMA therapy for patients with prior large-field RT involving substantial active marrow compared with patients who only had focal bone SBRT?

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

1 Answer available

For patients starting Pluvicto, do you have patients stop their ARPI?

This question is part of our collaboration with ASTRO to highlight impactful data from the 2026 Multidisciplinary Radiopharmaceutical Symposium. This ...

3 Answers available

How do you interpret isolated PSMA-avid sites in a patient with prostate cancer with no pelvic or RP LN uptake?

How do you discern false-positive PSMA PET sites? Is it typical to find metastatic disease without prior pelvic or RP node involvement?

4 Answers available

Would you continue serial PSMA PET scans after 2 negative scans for patients with a persistently rising PSA post-RT?

PSA > 2, and PSA doubling time < 1yr. Patient is resistant to ADT and did not tolerate the primary treatment. Would alternative PET imaging be r...

2 Answers available

How can you manage a patient with bilateral PCNs who requires Pluvicto administration?

The question is regarding the logistics management of the collection system.

1 Answer available

What is your experience with Pylarify vs. Posluma PSMA PET for prostate cancer and is one preferred over the other?

1 Answer available

How do you approach Lu-177 use in taxane-naive patients with metastatic prostate cancer?

With the recent publication of PSMAfore, what are your current criteria for offering Lu-177 therapy?

2 Answers available

For a patient post-prostatectomy with a high PSA (>1), a negative MRI pelvis, and a negative PSMA PET scan, do you pursue any other imaging?

FDG PET, Axumin PET, Bone scan? Or just proceed with salvage ADT/RT?

4 Answers available

How do you manage dry eye related to Pluvicto Lu-177?

2 Answers available

For persistent PSA elevation after prostatectomy, would you recommend salvage radiation if pathologically negative nodes, but regional and non-regional lymphadenopathy on PSMA PET?

Specifically, would you offer salvage radiation to a patient who underwent a prostatectomy with PLND and had a post-op PSA of 12 with pathology reveal...

2 Answers available